missed the prep opportunity? | laura waters, md, frcp
Published 3 years ago • 27 plays • Length 28:15Download video MP4
Download video MP3
Similar videos
-
8:23
con standpoint - laura waters, md, frcp
-
16:56
resistance considerations when choosing optimal treatment - laura waters, md, frcp
-
2:15
preview of update on insti toxicity | laura waters, md, frcp
-
16:10
managing toxicity in the complex hiv patient | laura waters md, frcp
-
12:17
challenges in routine hiv care in the covid 19 era - laura waters, md, frcp
-
16:50
avoiding and minimizing drug toxicity - laura waters, md, frcp
-
0:36
preview: highlights european hiv clinical forum 2021 | laura waters, md, frcp
-
24:01
state of the art: insti toxicities and their management | laura waters, md, frcp
-
8:57
الوقاية من فيروس الأيدز باستخدام حبوب بريب - prep
-
6:29
how to choose between truvada and descovy - preexposure prophylaxis (prep)
-
4:39
researchers find that some people can fight hiv without arv treatment
-
0:40
invitation by laura waters, md, frcp | european hiv clinical forum 2021
-
19:10
case discussion: how do drugs/patients impact need and type of monitoring | laura waters, md, frcp
-
14:12
let's talk about prep
-
31:34
long acting arv for treatment and prevention - clinical considerations | laura waters, md, frcp
-
28:57
arv toxicity and their management (including weight gain) - laura waters,md
-
5:24
people first charter - laura waters
-
8:45
waters, laura - do integrase inhibitors and/or taf lead to weight gain? pro
-
17:26
toxicity of different drugs classes and their clinical implication - laura waters, md, frcp
-
0:15
this is the reality of becoming a surgeon.
-
19:09
long-acting hiv drugs for treatment: data and potential implementation - laura waters
-
16:36
clinical review: new rt inhibitors – doravirine - laura waters